The early experience with ide-cel and cilta-cel underpinned the potency of anti-BCMA CAR T cell therapy in multiple myeloma, and triggered a rapid evolution in the treatment of the disease (15, 19). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.